2025-06-11-花旗集团-科金生物科学（COGT）_科进生物科学公司（COGT.O）_高达4亿美元的信贷安排_以里程碑为基础的批次提供_有效期至2027年_10页_232kb

Cogent Biosciences Credit Facility and Valuation

Overview

Cogent Biosciences secured a $400M credit facility with SLR Capital to support working capital and general business purposes, available through 2027.

Credit Facility Terms

• Total Facility: Up to $400M with $50M funded upfront.
• Milestones: Additional tranches based on future events:
  • $25M for positive Ph2 SUMMIT trial data.
  • $75M for positive Ph3 PEAK trial data.
  • $50M for $85M in drug revenue by June 30, 2027.
• Final Tranche: $200M available by mutual agreement.
• Maturity: June 2030, with interest rate at 4.75% plus greater of 1-month SOFR or 4.15%.
• Interest Payments: Suspended until June 2028.

Valuation

• Target Price: $15 per share.
• Expected Returns: 103.5% total return.
• Analysis Method: Discounted cash flow (DCF) with 2% terminal growth and 12.5% discount rate.

Risk Assessment

• Citi Rating: Buy / High Risk.
• Risks: High volatility due to biotech stock nature, clinical trial uncertainties, regulatory updates, and high development costs. Negative updates could lead to price downside.

Analyst Information

• David Lebowitz (CFA), Coverage Director.
• Ike Lee, Analyst.
• Affiliations: Citigroup Global Markets Inc., subject to potential conflicts of interest.

Key Metrics

Metric	Detail
Target Price	$15.00
Expected Share Return	103.5%
Expected Dividend Yield	0.0%
Market Cap Projection	$839M
12M Rating Catalyst	Buy/Hold/Sell Distribution: Not specified in summary.